HALT & REVERSE: Hsf1 activators lower cardiomyocyt damage; towards a novel approach to REVERSE atrial fibrillation

Autor: Bianca J. J. M. Brundel, Natasja M.S. de Groot, Denise M. S. van Marion, Ad J.J.C. Bogers, Eva A.H. Lanters, Herman Steen, Charles Kik, Maurits A. Allessie
Přispěvatelé: Cardiology, Cardiothoracic Surgery, Physiology, ICaR - Heartfailure and pulmonary arterial hypertension
Rok vydání: 2015
Předmět:
Male
medicine.medical_treatment
Cardioversion
Pulmonary vein
law.invention
Electrocardiography
Intraoperative Period
SUBSTRATE
Heat Shock Transcription Factors
law
Recurrence
Atrial Fibrillation
GOAT
Protocol
Myocytes
Cardiac
Prospective Studies
Prospective cohort study
Medicine(all)
Cardiopulmonary Bypass
medicine.diagnostic_test
Atrial fibrillation
General Medicine
Middle Aged
DNA-Binding Proteins
CARDIOVERSION
Treatment Outcome
Mapping
Cardiothoracic surgery
Pulmonary Veins
Research Design
Cardiology
cardiovascular system
Female
INTERVENTION
Pericardium
Adult
medicine.medical_specialty
Adolescent
PROTEOSTASIS
General Biochemistry
Genetics and Molecular Biology
PERSISTENT
Young Adult
Electropathology
Heat shock protein
Internal medicine
medicine
Cardiopulmonary bypass
HEAT-SHOCK PROTEINS
Humans
Heart Atria
Aged
Heat shock proteins
business.industry
Biochemistry
Genetics and Molecular Biology(all)
medicine.disease
MODEL
CONTRACTILE DYSFUNCTION
business
FOLLOW-UP
Transcription Factors
Zdroj: Lanters, E A H, van Marion, D M S, Kik, C, Steen, H, Bogers, A J J C, Allessie, M A, Brundel, B J J M & de Groot, N M S 2015, ' HALT & REVERSE: Hsf1 activators lower cardiomyocyt damage; towards a novel approach to REVERSE atrial fibrillation ', Journal of Translational Medicine, vol. 13, pp. 347 . https://doi.org/10.1186/s12967-015-0714-7
Journal of Translational Medicine, 13. BioMed Central Ltd.
Journal of Translational Medicine
Journal of Translational Medicine, 13. BioMed Central
Journal of translational medicine, 13(1):347. BioMed Central Ltd.
ISSN: 1479-5876
DOI: 10.1186/s12967-015-0714-7
Popis: Background Atrial fibrillation is a progressive arrhythmia, the exact mechanism underlying the progressive nature of recurrent AF episodes is still unknown. Recently, it was found that key players of the protein quality control system of the cardiomyocyte, i.e. Heat Shock Proteins, protect against atrial fibrillation progression by attenuating atrial electrical and structural remodeling (electropathology). HALT & REVERSE aims to investigate the correlation between electropathology, as defined by endo- or epicardial mapping, Heat Shock Protein levels and development or recurrence of atrial fibrillation following pulmonary vein isolation, or electrical cardioversion or cardiothoracic surgery. Study design This study is a prospective observational study. Three separate study groups are defined: (1) cardiothoracic surgery, (2) pulmonary vein isolation and (3) electrical cardioversion. An intra-operative high-resolution epicardial (group 1) or endocardial (group 2) mapping procedure of the atria is performed to study atrial electropathology. Blood samples for Heat Shock Protein determination are obtained at baseline and during the follow-up period at 3 months (group 2), 6 months (groups 1 and 2) and 1 year (group 1 and 2). Tissue samples of the right and left atrial appendages in patients in group 1 are analysed for Heat Shock Protein levels and for tissue characteristics. Early post procedural atrial fibrillation is detected by continuous rhythm monitoring, whereas late post procedural atrial fibrillation is documented by either electrocardiogram or 24-h Holter registration. Conclusion HALT & REVERSE aims to identify the correlation between Heat Shock Protein levels and degree of electropathology. The study outcome will contribute to novel diagnostic tools for the early recognition of clinical atrial fibrillation. Trial Registrations: Rotterdam Medical Ethical Committee MEC-2014-393, Dutch Trial Registration NTR4658
Databáze: OpenAIRE
Externí odkaz: